Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 11/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | SPR | P35270 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309442 | 1.00 | KDM4E (0.47) | KDM4EHSD11B1GAANPSR1SYK | |
| SCHEMBL308749 | 0.89 | PDE2A (0.49) | KDM4EHSD11B1GAANPSR1SPR | |
| SCHEMBL310141 | 0.89 | PDE2A (0.49) | KDM4EHSD11B1GAANPSR1SPR | |
| SCHEMBL308408 | 0.85 | SPR (0.55) | KDM4EHSD11B1GAANPSR1SYK | |
| SCHEMBL309552 | 0.85 | SPR (0.43) | KDM4EHSD11B1GAANPSR1SYK | |
| SCHEMBL309343 | 0.85 | SPR (0.43) | KDM4EHSD11B1GAANPSR1SYK | |
| SCHEMBL3770851 | 0.85 | SPR (0.43) | KDM4EHSD11B1GAANPSR1SYK | |
| SCHEMBL12965958 | 0.83 | HSD11B1 (0.53) | HSD11B1 | |
| SCHEMBL12965667 | 0.83 | HSD11B1 (0.53) | HSD11B1 | |
| Formic Acid SCHEMBL1430011 | 0.80 | HSD11B1 (0.50) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2313413-B1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES | CONVERGENCE PHARMACEUTICALS (GB) | 2012-05-16 | — | — | EP | disclosed |
| US-8093249-B2 | Pyrazolo[1,5-A]pyrimidine-carbonyl-piperazine derivatives | Convergence Pharmaceuticals Limited (GB) | 2012-01-10 | — | — | US | disclosed |
| US-8093249-B2 | Pyrazolo[1,5-A]pyrimidine-carbonyl-piperazine derivatives | Convergence Pharmaceuticals Limited (GB) | 2012-01-10 | — | — | US | disclosed |
| EP-2313413-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES | Convergence Pharmaceuticals Limited (GB) | 2011-04-27 | — | — | EP | disclosed |
| US-20100016330-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016330-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-21 | — | — | US | disclosed |
| WO-2010007074-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007074-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016330-A1 | Novel Derivatives | CACNB2, CACNA1B, CACNA1D | KDM4E 3426/4885HSD11B1 4779/4885GAA 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.